GLYCARDIAL DIAGNOSTICS, SL

Their core work

Glycardial Diagnostics is a Barcelona-based medical diagnostics SME focused on developing an in vitro diagnostic (IVD) device for the early detection of cardiac ischemia — a condition where the heart muscle receives insufficient blood supply, often a precursor to heart attack. The company's name suggests their technology is based on glycan or glycoprotein biomarkers, a relatively novel class of cardiac indicators compared to traditional enzymes like troponin. They took a single core product through the full EU SME Instrument pipeline, progressing from feasibility study (Phase 1) to full-scale development and commercialization (Phase 2), indicating a product-focused startup rather than a broad research organization.

What they specialise in

How they've shifted over time

Glycardial's entire H2020 footprint is a single technology trajectory: developing an IVD device for cardiac ischemia using what appears to be a glycan-based biomarker approach. The 2018 Phase 1 project was a feasibility and market assessment exercise (€50K), and the 2019–2022 Phase 2 project was the scale-up to full product development (€1.9M). There is no visible diversification or pivot — the organization has pursued one focused product idea from concept to commercialization. This is consistent with a startup built around a single proprietary technology rather than a research group with a broad portfolio.

They are a single-product diagnostics company that completed EU-funded development by 2022 — any future collaboration would likely center on clinical validation, regulatory approval (CE/IVD), distribution partnerships, or integration of their cardiac biomarker technology into broader diagnostic panels.

How they like to work

Glycardial has operated exclusively as project coordinator and entirely solo — both AGLYC projects recorded zero consortium partners, which is typical for the EU SME Instrument where individual companies apply for funding to develop their own product. This means there is no evidence of collaborative research behavior within H2020; they are a self-contained technology developer. A partner considering working with them should expect to be engaging a product company seeking licensees, clinical partners, or distributors rather than a traditional research consortium member.

Glycardial has no recorded consortium partners in H2020 — both projects were solo SME Instrument applications. Their network within the EU research ecosystem is effectively unknown from this data alone.

What sets them apart

Glycardial occupies a narrow but high-value niche: early-stage cardiac ischemia diagnostics using what appears to be a glycan biomarker approach, which would differentiate them from the dominant troponin and BNP-based tests already on the market. As an SME that successfully secured both phases of the EU SME Instrument for the same product, they have demonstrated proof of concept and investor-grade validation from the European Commission. For a hospital network, diagnostics company, or MedTech firm looking to license a differentiated cardiac IVD technology, Glycardial represents a focused acquisition or partnership target rather than a broad research collaborator.

Highlights from their portfolio

• AGLYC (Phase 2)
  The largest project (€1.9M, 2019–2022) represents a full product development cycle under the competitive EU SME Instrument Phase 2, signaling that the European Commission judged this technology commercially viable and investment-worthy.
• AGLYC (Phase 1)
  The 2018 feasibility study (€50K) is notable as the entry point that unlocked the larger Phase 2 grant, confirming a deliberate and successful EU funding strategy for a single core technology.